About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

ABCB1 SNPs as Predictors of PIPN | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDNCT05093023

ABCB1 SNPs as Predictors of PIPN

The study aim is to determine the allele frequencies of 1236 G\>A and 3435 G\>A in ABCB1 and study their association with the incidence and severity of paclitaxel-induced peripheral neuropathy while a...

Lead sponsor: Ain Shams University•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Ain Shams University

Age

18 - No limit years

Sex

FEMALE

Healthy Volunteers

No

Inclusion Criteria

•1. Egyptian females ≥18 years of age.
•2. Histologically confirmed Breast Cancer.
•3. Receiving conventional neoadjuvant or adjuvant weekly paclitaxel.
•4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
•5. Adequate organ reserves ((serum creatinine ≤1.5x upper normal limit (UNL), total bilirubin ≤1.5x UNL, absolute neutrophil count ≥1.5 x 10\^9/L, platelet count ≥100 x 10\^9/L, AST and ALT ≤3.0x UNL, and alkaline phosphatase ≤3.0x UNL).
•6. No major neurological disease or symptoms prior to the start of paclitaxel therapy.
•7. neither subjective nor objective evidence of metastatic disease.

Exclusion Criteria

•1. Pregnancy.
•2. Patients with recurrent or metastatic (local or distant) breast cancer.
•3. Neuropathic at the time of recruitment.
•4. History of neuropathy prior to recruitment.
•5. Previously exposed to taxanes or any other microtubule Inhibitors, or regimens including platinates.
•6. Patients currently receiving dose-dense biweekly taxane-containing regimens.

Related studies

HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity

NCT07586215 · Breast Cancer Metastatic

RC48-ADC in HER2-low Advanced Breast Cancer

NCT05831878 · Advanced Breast Cancer

RECRUITINGPhase 4

A Randomized, Self-controlled Post-marketing Clinical Study on the Comparison of Shengbai Oral Liquid and Leucogen Tablets in the Treatment of Moderate Neutropenia Caused by Anti-tumor Drugs in Breast Cancer Patients

NCT07578064 · Breast Cancer, Bone Marrow Suppression

RECRUITINGPhase 2

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

NCT07368998 · Breast Cancer

RECRUITINGPhase 2

Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

NCT06525766 · Anatomic Stage IV Breast Cancer AJCC v8, Estrogen-receptor-positive Breast Cancer, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 26, 2021Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment92

Start dateMar 2018

Last updatedOct 26, 2021

Condition

Paclitaxel Adverse Reaction Neuropathy;Peripheral Breast Cancer

Locations shown

Nasser's Institute Hospital

Cairo, Aghakhan

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 26, 2021Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions